Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NIS793 + mFOLFIRINOX
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
NIS793 + mFOLFIRINOX is an investigational combination therapy being evaluated for the treatment of pancreatic adenocarcinoma. NIS793 (letolizumab) is a fully human monoclonal antibody that targets and neutralizes transforming growth factor-beta (TGF-β), a cytokine often overexpressed in the tumor microenvironment that promotes immune evasion, fibrosis, and metastasis. mFOLFIRINOX is a standard-of-care chemotherapy regimen comprising oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil. By combining TGF-β inhibition with cytotoxic chemotherapy, the regimen aims to overcome the dense stroma and immunosuppressive environment characteristic of pancreatic tumors, potentially improving surgical resectability and long-term outcomes in the neoadjuvant setting.
- Other names
- letolizumab + mFOLFIRINOXNIS793 plus modified FOLFIRINOXNIS-793 plus modified FOLFIRINOXNIS 793 plus modified FOLFIRINOX
02
Targets
TGFB2 (Transforming growth factor beta 2)TGFB3 (Transforming growth factor beta 3)TGFB1 (Transforming growth factor Beta-1 proprotein)
Beyond the preview
Go deeper on NIS793 + mFOLFIRINOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NIS793 + mFOLFIRINOX.